Morgan Stanley Jaguar Health, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.08 - $809.55 $10,829 - $110 Million	135,367 Added 123.31%	245,148 $22,000
Q3 2022 Nov 14, 2022	BUY	$0.17 - $765.0 $6,322 - $28.4 Million	37,189 Added 51.23%	109,781 $17,000
Q2 2022 Oct 27, 2022	SELL	$0.27 - $0.71 $27,134 - $71,353	-100,498 Reduced 58.06%	72,592 $21,000
Q2 2022 Aug 15, 2022	SELL	$0.27 - $0.71 $27,134 - $71,353	-100,498 Reduced 58.06%	72,592 $21,000
Q1 2022 Oct 27, 2022	BUY	$0.38 - $1.07 $38,189 - $107,532	100,498 Added 138.44%	173,090 $122,000
Q1 2022 May 13, 2022	BUY	$0.38 - $1.07 $44,911 - $126,462	118,189 Added 215.28%	173,090 $122,000
Q4 2021 Feb 14, 2022	BUY	$1.03 - $2.48 $20,472 - $49,292	19,876 Added 56.75%	54,901 $57,000
Q3 2021 Nov 15, 2021	BUY	$2.14 - $4.95 $74,953 - $173,373	35,025 New	35,025 $79,000

Ticker JAGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 119,861,000
Market Cap $127M
Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfecti...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.